好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A challenging case of intractable seizures in a pediatric patient with anti-GAD65 encephalitis
Autoimmune Neurology
P2 - Poster Session 2 (5:30 PM-6:30 PM)
15-019

We describe a case of autoimmune encephalitis associated with anti-glutamic acid decarboxylase (GAD 65) antibodies in a girl with type 1 Diabetes Mellitus (T1DM).

Anti-GAD65 antibodies are associated with neurological syndromes such as limbic encephalitis, refractory epilepsy, stiff-person syndrome, Miller-Fisher syndrome, cerebellar ataxia, and opsoclonus myoclonus syndrome and non-neurological conditions such as T1DM and thyroiditis. Very few pediatric cases with anti-GAD65 encephalitis are reported to date. Concomitant T1DM is even rarer and complicates management.

Case Report

A 13 year old girl with developmental delay, ventriculomegaly, hyperglycemia managed with metformin and remote history of seizures, well controlled on topiramate for 5 years, was hospitalized for breakthrough seizures and altered mental status. She had head jerking and generalized convulsion with right temporal electrographic onset; and 3 Hz repetitive eye blinking, initially without electrographic correlate, but later with right temporal electrographic onset. Seizures were initially managed with addition of levetiracetam. As inpatient, she had worsening of mental status and developed diabetic ketoacidosis requiring airway protection. Insulin was started post clinical diagnosis of T1DM. Clinical and electrographic seizures worsened in frequency. Interictal EEG showed independent bilateral frontal; left temporal spikes; independent right temporal periodic lateralized epileptiform discharges; and multifocal stimulus-induced rhythmic, periodic, or ictal discharges. Addition of fosphenytoin, lacosamide and continuous midazolam infusion could not control seizures. Infectious work-up was non-revealing. Anti-GAD65 antibody levels were elevated in serum (207 nmol/L) and CSF (24 nmol/L). No other testable autoimmune antibodies were detected. Intravenous high dose corticosteroids and intravenous immunoglobulin resulted in complete resolution of clinical and electrographic seizures but minimal improvement in her mental status. Plasma exchange (PLEX) improved mental status. She is receiving further rounds of PLEX.

Physicians should be aware of this rare entity of anti-GAD65 encephalitis. This can occur in conjunction with T1DM. Prompt recognition and aggressive immunological treatment is critical.

 

Authors/Disclosures
Supriya Kairamkonda, MD
PRESENTER
No disclosure on file
Kapil Arya, MBBS, DA, FAAP, FACNS, FAAN (UAMS - Pediatric Neurology) Dr. Arya has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Arya has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Arya has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scholar Rock.
Genevieve K. Gabriel, MD (Robert Wood Johnson University Hospital) No disclosure on file
Aravindhan Veerapandiyan, MD (Arkansas Childrens Hospital/UAMS) Dr. Veerapandiyan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen, Novartis,Edgewise Therapeutics, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Inc., UCB Pharma, Catalyst, Entrada, Lupin, Percheron, ITF. Dr. Veerapandiyan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Veerapandiyan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Muscle and Nerve. The institution of Dr. Veerapandiyan has received research support from AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, RegenxBio, SolodBio and Sarepta Therapeutics. Dr. Veerapandiyan has received personal compensation in the range of $5,000-$9,999 for serving as a MD with PPMD, MDA.